Deremer DL - Search Results

1

Antiangiogenic therapy for cancer: an update.

Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Al-Husein B, et al. Among authors: deremer dl. Pharmacotherapy. 2012 Dec;32(12):1095-111. doi: 10.1002/phar.1147. Pharmacotherapy. 2012. PMID: 23208836 Free PMC article. Review.

2

Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence.

Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC. Willis LM, et al. Among authors: deremer dl. Clin Sci (Lond). 2011 Apr;120(8):307-19. doi: 10.1042/cs20100389. Clin Sci (Lond). 2011. PMID: 21488224 Review.

3

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.

Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR. Goc A, et al. Among authors: deremer dl. Oncotarget. 2014 Feb 15;5(3):775-87. doi: 10.18632/oncotarget.1770. Oncotarget. 2014. PMID: 24519956 Free PMC article.

4

Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.

DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi AS. DeRemer DL, et al. Pharmacotherapy. 2016 Feb;36(2):218-29. doi: 10.1002/phar.1703. Pharmacotherapy. 2016. PMID: 26890915 Review.

5

Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.

Andrick B, Alwhaibi A, DeRemer DL, Quershi S, Khan R, Bryan LJ, Somanath PR, Pantin J. Andrick B, et al. Among authors: deremer dl. Br J Haematol. 2018 Sep;182(5):712-714. doi: 10.1111/bjh.14855. Epub 2017 Jul 24. Br J Haematol. 2018. PMID: 28737280 Free article. No abstract available.

6

The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.

Gwynn ME, DeRemer DL. Gwynn ME, et al. Among authors: deremer dl. Ann Pharmacother. 2018 Jan;52(1):60-68. doi: 10.1177/1060028017727546. Epub 2017 Aug 23. Ann Pharmacother. 2018. PMID: 28831813 Review.

7

Investigational drugs targeting FLT3 for leukemia.

Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Ustun C, et al. Among authors: deremer dl. Expert Opin Investig Drugs. 2009 Oct;18(10):1445-56. doi: 10.1517/13543780903179278. Expert Opin Investig Drugs. 2009. PMID: 19671038 Review.

8

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D. Bradley AM, et al. Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Am J Health Syst Pharm. 2013. PMID: 23515511 Review.

9

Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.

Luboff AJ, DeRemer DL. Luboff AJ, et al. Among authors: deremer dl. Ann Pharmacother. 2024 Dec;58(12):1229-1237. doi: 10.1177/10600280241241531. Epub 2024 Apr 2. Ann Pharmacother. 2024. PMID: 38566315 Review.

10

Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.

Lewis G, Hall P, Eisa N, Deremer D, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Lewis G, et al. Acta Haematol. 2010;124(4):206-13. doi: 10.1159/000321504. Epub 2010 Nov 12. Acta Haematol. 2010. PMID: 21071929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters